GYRE THERAPEUTICS, INC. (GYRE) › Cash & EquivalentsGYRE THERAPEUTICS, INC. (GYRE) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2008-12-31: $51.20M2009-12-31: $83.91M2010-12-31: $165.85M2011-12-31: $107.28M2012-12-31: $3.40M2013-12-31: $2.83M2014-12-31: $1.54M2015-12-31: $29.10M2016-12-31: $10.26M2017-12-31: $14.47M2018-12-31: $31.21M2019-12-31: $15.37M2020-12-31: $30.36M2021-12-31: $44.35M2022-12-31: $25.18M2023-12-31: $33.51M2024-12-31: $11.81M2025-12-31: $37.07M$37.07M2008-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$37.07M+213.8%2026-03-13Balance as of period end2024-12-31$11.81M-64.7%2026-03-13Balance as of period end2023-12-31$33.51M+33.1%2025-03-17Balance as of period end2022-12-31$25.18M-43.2%2024-03-27Balance as of period end2021-12-31$44.35M+46.1%2023-03-30Balance as of period end2020-12-31$30.36M+97.5%2022-03-31Balance as of period end2019-12-31$15.37M-50.8%2021-03-04Balance as of period end2018-12-31$31.21M+115.7%2020-02-20Balance as of period end2017-12-31$14.47M+41.0%2019-03-08Balance as of period end2016-12-31$10.26M-64.7%2018-03-19Balance as of period end2015-12-31$29.10M+1784.5%2018-03-19Balance as of period end2014-12-31$1.54M-45.4%2017-03-08Balance as of period end2013-12-31$2.83M-16.8%2016-03-09Balance as of period end2012-12-31$3.40M-96.8%2016-03-09Balance as of period end2011-12-31$107.28M-35.3%2015-03-16Balance as of period end2010-12-31$165.85M+97.7%2014-03-14Balance as of period end2009-12-31$83.91M+63.9%2013-03-15Balance as of period end2008-12-31$51.20M—2012-03-06Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)